These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 37983118

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Upadacitinib (Rinvoq): A second JAK inhibitor for ulcerative colitis.
    Med Lett Drugs Ther; 2022 Sep 05; 64(1658):142-144. PubMed ID: 36094554
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul 10; 65(1680):105-112. PubMed ID: 37418329
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ.
    J Crohns Colitis; 2021 Jun 22; 15(6):950-959. PubMed ID: 33475734
    [Abstract] [Full Text] [Related]

  • 11. Etrasimod for the treatment of ulcerative colitis.
    Wils P, Peyrin-Biroulet L.
    Immunotherapy; 2023 Apr 22; 15(5):311-321. PubMed ID: 36789612
    [Abstract] [Full Text] [Related]

  • 12. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG.
    Lancet; 2023 Apr 08; 401(10383):1159-1171. PubMed ID: 36871574
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Etrasimod: First Approval.
    Shirley M.
    Drugs; 2024 Feb 08; 84(2):247-254. PubMed ID: 38388871
    [Abstract] [Full Text] [Related]

  • 15. Table: drugs for ulcerative colitis.
    Med Lett Drugs Ther; 2018 Jul 02; 60(1550):e114. PubMed ID: 30036353
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Etrasimod for ulcerative colitis: evaluating phase III results.
    Matsuoka K, Hibi T.
    Nat Rev Gastroenterol Hepatol; 2023 Dec 02; 20(12):762-763. PubMed ID: 37221319
    [No Abstract] [Full Text] [Related]

  • 19. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H.
    Expert Rev Gastroenterol Hepatol; 2021 Jun 02; 15(6):711-722. PubMed ID: 33599181
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.